Objectives: To investigate the prevalence and potential risk factors of obesity after therapy for childhood acute lymphoblastic leukemia (ALL). Study Design: 39 ALL patients (age 10.7–20.5 years) who were in first remission for 3.4–14.6 years after standardized treatment with chemotherapy plus cranial irradiation (n = 25) or with chemotherapy alone (n = 14) were examined. After fasting overnight, the following parameters were investigated: body mass index (BMI) of patients and their parents; patients’ BMI before ALL therapy; serum free thyroxin, growth hormone-dependent factors, estradiol, testosterone, cortisol, leptin and c-peptide; fat-free mass (bioelectrical impedance); resting metabolic rate (RMR, indirect calorimetry); caloric intake (24-hour recall); and physical activity (questionnaire). RMR data were applied to the fat-free mass and compared with 83 controls. Results: The prevalence of obesity (criterion: BMI > 2 SDS) was significantly (p < 0.05) higher after ALL therapy (38%; irradiated patients 48%, non-irradiated patients 21%) than before therapy (3%). Compared to non-irradiated patients, irradiated patients had significantly lower RMRs (–1.07 ± 0.24 vs. –0.32 ± 0.21 SDS; p < 0.05), reduced physical activity levels (1.41 ± 0.03 vs. 1.52 ± 0.03; p < 0.05), and lower concentrations of insulin-like growth factor-binding protein-3 (–0.65 ± 0.17 vs. 0.25 ± 0.33 SDS; p < 0.05) and of free thyroxin (1.17 ± 0.06 vs. 1.38 ± 0.08 ng/dl; p < 0.05). Caloric intake was adequate. Conclusions: After ALL during childhood, patients face a higher risk of obesity. In the cranially irradiated patients, the likely causes are low physical activity, RMRs and hormonal insufficiency.

Keywords:
Caloric intake, Children, Malignancy, Metabolic rate, Physical activity, Weight
1.
Sainsbury CPQ, Newcombe RG, Hughes IA: Weight gain and height velocity during prolonged first remission from acute lymphoblastic leukaemia. Arch Dis Child 1985;60:832–836.
2.
Davies HA, Didcock E, Didi M, Ogilvy-Stuart A, Wales JK, Shalet SM: Growth, puberty and obesity after treatment for leukaemia. Acta Paediatr 1995 (suppl 411):45–50.
3.
Didi M, Didcock E, Davies HA, Ogilvy-Stuart AL, Wales JK, Shalet SM: High incidence of obesity in young adults after treatment of acute lymphoblastic leukemia in childhood. J Pediatr 1995;127:63–67.
4.
Groot-Loonen JJ, Otten BJ, van’t Hof MA, Lippens RJ, Stoelinga GB: Influence of treatment modalities on body weight in acute lymphoblastic leukemia. Med Pediatr Oncol 1996;27:92–97.
5.
Odame I, Reilly JJ, Gibson BE, Donaldson MD: Patterns of obesity in boys and girls after treatment for acute lymphoblastic leukaemia. Arch Dis Child 1994;71:147–149.
6.
Schell MJ, Ochs JJ, Schriock EA, Carter M: A method of predicting adult height and obesity in long-term survivors of childhood acute lymphoblastic leukaemia. J Clin Oncol 1992;10:128–133.
7.
Van Dongen-Melman JE, Hokken-Koelega AC, Hahlen K, De Groot A, Tromp CG, Egeler RM: Obesity after sucessful treatment of acute lymphoblastic leukemia in childhood. Pediatr Res 1995;38:86–90.
8.
Zee P, Chen CH: Prevalence of obesity in children after therapy for acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 1986;8:294–299.
9.
Mayer EI, Wassermann U, Dopfer RE, Ranke MB, Niethammer D: Schädelbestrahlung als Ursache für Adipositas nach ALL-Therapie im Kindesalter (abstract). Monatsschr Kinderkd 1996;144 (suppl 1):41.
10.
Henze G, Langermann HJ, Fengler R, Brandeis M, Evers K, Gadner H, Hinderfeld L, Jobke A, Kornhuber B, Lampert F, Lasson U, Ludwig R, Müller-Weihrich S, Neidhardt M, Nessler G, Niethammer D, Rister M, Ritter J, Schaaff A, Schellong G, Stollmann B, Treuner J, Wahlen W, Weinel P, Wehlinger H, Riehm H: Therapiestudie BFM 79/81 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen: Intensivierte Reinduktionstherapie für Patientengruppen mit unterschiedlichem Rezidivrisiko. Klin Pädiatr 1982;194:195–203.
11.
Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Welte K, Gadner H, Riehm H: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122–3133.
12.
Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V, Ludwig R, Ritter J, Stollmann B, Henze G: Die Corticoisteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83). Klin Pädiatr 1987;199:151–160.
13.
Schrappe M, Reiter A, Sauter S, Ludwig WD, Wormann B, Harbott J, Bender-Götze C, Dorffel W, Dopfer R, Frey E, Havers W, Henze G, Kühl J, Richter R, Ritter J, Treuner J, Zintl F, Odenwald E, Welte K, Riehm H: Konzeption und Zwischenergebnis der Therapiestudie ALL-BFM 90 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen: Die Bedeutung des initialen Therapieansprechens in Blut und Knochenmark. Klin Pädiatr 1994;206:208–221.
14.
Torun B, Davies PSW, Livingstone MBE, Paolisso M, Sacket R, Spur GB: Energy requirements and dietary energy recommendations for children and adolescents 1 to 18 years old. Eur J Clin Nutr 1996;50(suppl 1):37–80.
15.
Rolland-Cachera MF, Cole TJ, Sempe J, Tichet J, Rossignol C, Charraud A: Body mass index variations: Centiles from birth to 87 years. Eur J Clin Nutr 1991;45:13–21.
16.
Blum WF, Breier BH: Radioimmunoassays for IGFs and IGFBPs. Growth Regul 1994(suppl 1):11–19.
17.
Blum WF, Englaro P, Hanitsch S, Juul A, Hertel NT, Müller J, Skakkebaek NE, Heiman ML, Birkett M, Attanasio AM, Kiess W, Rascher W: Plasma leptin levels in healthy children and adolescents: Dependence on body mass index, body fat mass, gender, pubertal stage, and testosterone. J Clin Endocrinol Metab 1997;82:2904–2910.
18.
Reilly JJ, Blacklock CJ, Dale E, Donaldson M, Gibson BES: Resting metabolic rate and obesity in childhood acute lymphoblastic leukaemia. Int J Obesity Relat Metab Disord 1996;20:1130–1132.
19.
Warner JT, Bell W, Webb DKH, Gregory JW: Daily energy expenditure and physical activity in survivors of childhood malignancy. Pediatr Res 1998;43:607–613.
20.
Weinsier RL, Nelson KM, Hensrud DD, Darnell BE, Hunter GR, Schutz Y: Metabolic predictors of obesity. Contribution of resting energy expenditure, thermic effect of food, and fuel utilization to four-year weight gain of post-obese and never-obese women. J Clin Invest 1995;95:980–985.
21.
Jenney MEM, Faragher EB, Morris-Jones PH, Woodcock A: Lung function and exercise capacity in survivors of childhood leukaemia. Med Pediatr Oncol 1995;24:222–230.
22.
Bingham SA, Gill C, Welch A, Day K, Cassidy A, Khaw KT, Sneyd MJ, Key TJ, Roe L, Day NE: Comparison of dietary assessment methods in nutritional epidemiology: Weighed records vs. 24 h recalls, food-frequency questionnaires and estimated-diet records. Br J Nutr 1994;72:619–643.
23.
Crowne EC, Moore C, Wallace WH, Ogilvy-Stuart AL, Addison GM, Morris-Jones PH, Shalet SM: A novel variant of growth hormone (GH) insufficiency following low dose cranial irradiation. Clin Endocrinol (Oxf) 1992;36:59–68.
24.
Cowan FJ, Gregory JW: Discontinuing growth hormone and early metabolic effects (abstract). Horm Res 1997;48(suppl 2):74.
25.
Wolf M, Weigert A, Kreymann G: Body composition and energy expenditure in thyroidectomized patients during short-term hypothyroidism and thyrotropin-suppressive thyroxine therapy. Eur J Endocrinol 1996;134:168–173.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.